|
1
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verhoest G, Shariat SF, Chromecki TF,
Raman JD, Margulis V, Novara G, Seitz C, Remzi M, Rouprêt M, Scherr
DS and Bensalah K: Predictive factors of recurrence and survival of
upper tract urothelial carcinomas. World J Urol. 29:495–501. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lai MN, Wang SM, Chen PC, Chen YY and Wang
JD: Population-based case-control study of Chinese herbal products
containing aristolochic acid and urinary tract cancer risk. J Natl
Cancer Inst. 102:179–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Taiwan Health Promotion Administration
Ministry of Health and Welfare Taiwan, . Cancer Registry Annual
Report, 2014 Taiwan. 1212016.
|
|
6
|
Rouprêt M, Babjuk M, Compérat E, Zigeuner
R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW,
Kaasinen E, et al: European association of urology guidelines on
upper urinary tract urothelial cell carcinoma: 2015 Update. Eur
Urol. 68:868–879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kikuchi E, Margulis V, Karakiewicz PI,
Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer
A, et al: Lymphovascular invasion predicts clinical outcomes in
patients with node-negative upper tract urothelial carcinoma. J
Clin Oncol. 27:612–618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parsons DW, Wang TL, Samuels Y, Bardelli
A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK,
et al: Colorectal cancer: Mutations in a signalling pathway.
Nature. 436:7922005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cordes I, Kluth M, Zygis D, Rink M, Chun
F, Eichelberg C, Dahlem R, Fisch M, Höppner W, Wagner W, et al:
PTEN deletions are related to disease progression and unfavourable
prognosis in early bladder cancer. Histopathology. 63:670–677.
2013.PubMed/NCBI
|
|
11
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stokoe D, Stephens LR, Copeland T, Gaffney
PR, Reese CB, Painter GF, Holmes AB, McCormick F and Hawkins PT:
Dual role of phosphatidylinositol-3,4,5-trisphosphate in the
activation of protein kinase B. Science. 277:567–570. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sabatini DM: mTOR and cancer: Insights
into a complex relationship. Nat Rev Cancer. 6:729–734. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hay N: The Akt-mTOR tango and its
relevance to cancer. Cancer Cell. 8:179–183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gallay N, Dos Santos C, Cuzin L, Bousquet
M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C and
Récher C: The level of AKT phosphorylation on threonine 308 but not
on serine 473 is associated with high-risk cytogenetics and
predicts poor overall survival in acute myeloid leukaemia.
Leukemia. 23:1029–1038. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Freudlsperger C, Horn D, Weißfuß S,
Weichert W, Weber KJ, Saure D, Sharma S, Dyckhoff G, Grabe N,
Plinkert P, et al: Phosphorylation of AKT(Ser473) serves as an
independent prognostic marker for radiosensitivity in advanced head
and neck squamous cell carcinoma. Int J Cancer. 136:2775–2785.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Campbell IG, Russell SE, Choong DY,
Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB and
Phillips WA: Mutation of the PIK3CA gene in ovarian and breast
cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kirkegaard T, Witton CJ, McGlynn LM, Tovey
SM, Dunne B, Lyon A and Bartlett JM: AKT activation predicts
outcome in breast cancer patients treated with tamoxifen. J Pathol.
207:139–146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okano J, Snyder L and Rustgi AK: Genetic
alterations in esophageal cancer. Methods Mol Biol. 222:131–145.
2003.PubMed/NCBI
|
|
21
|
Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL
and Reddy SA: The PI 3-kinase/Akt signaling pathway is activated
due to aberrant Pten expression and targets transcription factors
NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene.
23:8571–8580. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Broderick DK, Di C, Parrett TJ, Samuels
YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD and
Yan H: Mutations of PIK3CA in anaplastic oligodendrogliomas,
high-grade astrocytomas, and medulloblastomas. Cancer Res.
64:5048–5050. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Knowles MA, Platt FM, Ross RL and Hurst
CD: Phosphatidylinositol 3-kinase (PI3K) pathway activation in
bladder cancer. Cancer Metastasis Rev. 28:305–316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Askham JM, Platt F, Chambers PA, Snowden
H, Taylor CF and Knowles MA: AKT1 mutations in bladder cancer:
Identification of a novel oncogenic mutation that can co-operate
with E17K. Oncogene. 29:150–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
28
|
Clark PE, Agarwal N, Biagioli MC,
Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel
TM, Lele SM, et al: Bladder cancer. J Natl Compr Canc Netw.
11:446–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rouprêt M, Babjuk M, Compérat E, Zigeuner
R, Sylvester R, Burger M, Cowan N, Böhle A, Van Rhijn BW, Kaasinen
E, et al: European guidelines on upper tract urothelial carcinomas:
2013 Update. Eur Urol. 63:1059–1071. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weng WH, Ahlén J, Aström K, Lui WO and
Larsson C: Prognostic impact of immunohistochemical expression of
ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res.
11:6198–6204. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gonzalez-Roibon ND, Chaux A, Al-Hussain T,
Osunkoya AO, Bezerra SM, Hicks J, Epstein JI and Netto GJ:
Dysregulation of mammalian target of rapamycin pathway in
plasmacytoid variant of urothelial carcinoma of the urinary
bladder. Hum Pathol. 44:612–622. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rieken M, Shariat SF, Karam JA, Foerster
B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, et
al: Frequency and prognostic value of PTEN loss in patients with
upper tract urothelial carcinoma treated with radical
nephroureterectomy. J Urol. 198:1269–1277. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qian CN, Furge KA, Knol J, Huang D, Chen
J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, et al:
Activation of the PI3K/AKT pathway induces urothelial carcinoma of
the renal pelvis: Identification in human tumors and confirmation
in animal models. Cancer Res. 69:8256–8264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Munari E, Fujita K, Faraj S, Chaux A,
Gonzalez-Roibon N, Hicks J, Meeker A, Nonomura N and Netto GJ:
Dysregulation of mammalian target of rapamycin pathway in upper
tract urothelial carcinoma. Hum Pathol. 44:2668–2676. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Makboul R, Refaiy A, Abdelkawi IF, Hameed
DA, Elderwy AA, Shalaby MM, Merseburger AS and Hussein MR:
Alterations of mTOR and PTEN protein expression in schistosomal
squamous cell carcinoma and urothelial carcinoma. Pathol Res Pract.
212:385–392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsuruta H, Kishimoto H, Sasaki T, Horie Y,
Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M, et
al: Hyperplasia and carcinomas in Pten-deficient mice and reduced
PTEN protein in human bladder cancer patients. Cancer Res.
66:8389–8396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Platt FM, Hurst CD, Taylor CF, Gregory WM,
Harnden P and Knowles MA: Spectrum of phosphatidylinositol 3-kinase
pathway gene alterations in bladder cancer. Clin Cancer Res.
15:6008–6017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Koletsas N, Koletsa T, Choidas S,
Anagnostopoulos K, Touloupidis S, Zaramboukas T, Raptou G,
Papadopoulos N and Lambropoulou M: Immunohistochemical
investigation of HER/AKT/mTOR pathway and cellular adhesion
molecules in urothelial carcinomas. Patholog Res Int.
2017:67941502017.PubMed/NCBI
|
|
40
|
Brugge J, Hung MC and Mills GB: A new
mutational AKTivation in the PI3K pathway. Cancer Cell. 12:104–107.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Franke TF, Kaplan DR, Cantley LC and Toker
A: Direct regulation of the Akt proto-oncogene product by
phosphatidylinositol-3,4-bisphosphate. Science. 275:665–668. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kreisberg JI, Malik SN, Prihoda TJ,
Bedolla RG, Troyer DA, Kreisberg S and Ghosh PM: Phosphorylation of
Akt (Ser473) is an excellent predictor of poor clinical outcome in
prostate cancer. Cancer Res. 64:5232–5236. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vincent EE, Elder DJ, Thomas EC, Phillips
L, Morgan C, Pawade J, Sohail M, May MT, Hetzel MR and Tavaré JM:
Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt
protein kinase activity in human non-small cell lung cancer. Br J
Cancer. 104:1755–1761. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shin E, Choi CM, Kim HR, Jang SJ and Park
YS: Immunohistochemical characterization of the mTOR pathway in
stage-I non-small-cell lung carcinoma. Lung Cancer. 89:13–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cha EK, Shariat SF, Kormaksson M, Novara
G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner
R, et al: Predicting clinical outcomes after radical
nephroureterectomy for upper tract urothelial carcinoma. Eur Urol.
61:818–825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Margulis V, Shariat SF, Matin SF, Kamat
AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD and Wood CG;
Upper Tract Urothelial Carcinoma CollaborationThe Upper Tract
Urothelial Carcin, : Outcomes of radical nephroureterectomy: A
series from the upper tract urothelial carcinoma collaboration.
Cancer. 115:1224–1233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ehdaie B, Chromecki TF, Lee RK, Lotan Y,
Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT,
et al: Obesity adversely impacts disease specific outcomes in
patients with upper tract urothelial carcinoma. J Urol. 186:66–72.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Izquierdo L, Truan D, Mengual L, Mallofré
C and Alcaraz A: HER-2/AKT expression in upper urinary tract
urothelial carcinoma: Prognostic implications. Anticancer Res.
30:2439–2445. 2010.PubMed/NCBI
|
|
49
|
Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y,
Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, et
al: Concomitant carcinoma in situ is a feature of aggressive
disease in patients with organ confined urothelial carcinoma
following radical nephroureterectomy. Urol Oncol. 30:252–258. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Poon SL, Pang ST, McPherson JR, Yu W,
Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, et al:
Genome-wide mutational signatures of aristolochic acid and its
application as a screening tool. Sci Transl Med. 5:197ra1012013.
View Article : Google Scholar : PubMed/NCBI
|
